Literature DB >> 19092836

Integrative biology--a strategy for systems biomedicine.

Edison T Liu1.   

Abstract

The precision of genome sequences, together with advanced computational approaches, allows complex, clinically relevant biological systems to be examined. Here, I describe the experiences of the Genome Institute of Singapore (GIS) in using genome-to-systems strategies to accelerate biomedical research. To maximize clinically relevant output, we have explored an organizational strategy that encourages coordinated experimentation among investigators with diverse skills and interests through building a culture of integrative science. Our experience suggests that systems biomedicine is a real and potentially fruitful strategy for translational research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19092836     DOI: 10.1038/nrg2488

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  25 in total

1.  A global map of p53 transcription-factor binding sites in the human genome.

Authors:  Chia-Lin Wei; Qiang Wu; Vinsensius B Vega; Kuo Ping Chiu; Patrick Ng; Tao Zhang; Atif Shahab; How Choong Yong; YuTao Fu; Zhiping Weng; JianJun Liu; Xiao Dong Zhao; Joon-Lin Chew; Yen Ling Lee; Vladimir A Kuznetsov; Wing-Kin Sung; Lance D Miller; Bing Lim; Edison T Liu; Qiang Yu; Huck-Hui Ng; Yijun Ruan
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

2.  Frequency of Smad gene mutations in human cancers.

Authors:  G J Riggins; K W Kinzler; B Vogelstein; S Thiagalingam
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

3.  Evolution of the mammalian transcription factor binding repertoire via transposable elements.

Authors:  Guillaume Bourque; Bernard Leong; Vinsensius B Vega; Xi Chen; Yen Ling Lee; Kandhadayar G Srinivasan; Joon-Lin Chew; Yijun Ruan; Chia-Lin Wei; Huck Hui Ng; Edison T Liu
Journal:  Genome Res       Date:  2008-08-05       Impact factor: 9.043

4.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

Authors:  Lance D Miller; Johanna Smeds; Joshy George; Vinsensius B Vega; Liza Vergara; Alexander Ploner; Yudi Pawitan; Per Hall; Sigrid Klaar; Edison T Liu; Jonas Bergh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

5.  Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

Authors:  Yan Zhao; Jing Tan; Li Zhuang; Xia Jiang; Edison T Liu; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-21       Impact factor: 11.205

6.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

Review 7.  MDM2 inhibitors for cancer therapy.

Authors:  Lyubomir T Vassilev
Journal:  Trends Mol Med       Date:  2006-11-28       Impact factor: 11.951

8.  HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Authors:  D A Berry; H B Muss; A D Thor; L Dressler; E T Liu; G Broadwater; D R Budman; I C Henderson; M Barcos; D Hayes; L Norton
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

9.  DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.

Authors:  Xia Jiang; Jing Tan; Jingsong Li; Saul Kivimäe; Xiaojing Yang; Li Zhuang; Puay Leng Lee; Mark T W Chan; Lawrence W Stanton; Edison T Liu; Benjamin N R Cheyette; Qiang Yu
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

10.  The genomic landscapes of human breast and colorectal cancers.

Authors:  Laura D Wood; D Williams Parsons; Siân Jones; Jimmy Lin; Tobias Sjöblom; Rebecca J Leary; Dong Shen; Simina M Boca; Thomas Barber; Janine Ptak; Natalie Silliman; Steve Szabo; Zoltan Dezso; Vadim Ustyanksky; Tatiana Nikolskaya; Yuri Nikolsky; Rachel Karchin; Paul A Wilson; Joshua S Kaminker; Zemin Zhang; Randal Croshaw; Joseph Willis; Dawn Dawson; Michail Shipitsin; James K V Willson; Saraswati Sukumar; Kornelia Polyak; Ben Ho Park; Charit L Pethiyagoda; P V Krishna Pant; Dennis G Ballinger; Andrew B Sparks; James Hartigan; Douglas R Smith; Erick Suh; Nickolas Papadopoulos; Phillip Buckhaults; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein
Journal:  Science       Date:  2007-10-11       Impact factor: 47.728

View more
  4 in total

1.  Reverse engineering biomolecular systems using -omic data: challenges, progress and opportunities.

Authors:  Chang F Quo; Chanchala Kaddi; John H Phan; Amin Zollanvari; Mingqing Xu; May D Wang; Gil Alterovitz
Journal:  Brief Bioinform       Date:  2012-07       Impact factor: 11.622

2.  A Bayesian analysis of the chromosome architecture of human disorders by integrating reductionist data.

Authors:  Frank Emmert-Streib; Ricardo de Matos Simoes; Shailesh Tripathi; Galina V Glazko; Matthias Dehmer
Journal:  Sci Rep       Date:  2012-07-20       Impact factor: 4.379

3.  Systems biology: the next frontier for bioinformatics.

Authors:  Vladimir A Likić; Malcolm J McConville; Trevor Lithgow; Antony Bacic
Journal:  Adv Bioinformatics       Date:  2011-02-09

Review 4.  State of the art in silico tools for the study of signaling pathways in cancer.

Authors:  Vanessa Medina Villaamil; Guadalupe Aparicio Gallego; Isabel Santamarina Cainzos; Manuel Valladares-Ayerbes; Luis M Antón Aparicio
Journal:  Int J Mol Sci       Date:  2012-05-29       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.